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Introduction
With an aging of the population [2], the
population's needs for health services have
increased in the European Union (EU-27) as
well as in Slovenia. Because of this increases
the burden on the country’s local public health
services and care have increased. The policy
response is to save or reduce their operating
costs. These policy measures include the
rational use of medicinal products and public
procurement of cheaper medicinal products.
They [1] noted that the expenditures on
medicinal products have increased within the
EU member states, and therefore argue that
the market regulation and pricing of drugs and
reimbursement of medicinal products is an
important tool to control public spending for
medicinal products.
The government with legislation and
economic policy measures seek to reduce and
to have under control public spending for medicinal
products. The purpose of the price regulation
system of medicinal products is to reduce public
expenditures for pharmaceutical products that
are charged by the health insurers and are
aimed for finding the optimum balance between
maintaining the access to essential medicinal
products and the rational use of public funds for
medicinal products. The price for medicinal
products is only one of the essential factors for
the public expenditures. [9], [10]
During the past decades, several EU
countries, as well as some other countries (e.g.
New Zealand, Australia, Canada and South
Korea) ([7], [17]), have implemented various
forms of price regulation. The aim of the price
regulation for medicinal products is to control
the costs and the health expenditures for
prescription of drugs. Authors [6] and [3]
believe that price regulation is one of the most
important tools by which economic policy
measures can be used to control and limit the
costs of medicinal products. The growth of the
public expenditures for medicinal products is
the one of the influencing factors for the
increase in public spending in health care in
most developed countries. To limit the growth of
expenditures for medicinal products the
competent authorities, particularly in EU-27,
initiated regulatory measures, which attempt to
influence to the market developments,
especially on the supply side [12]. EU countries
have different national pharmaceutical systems,
not only because of different historical, political,
legal and economic trends, but also because of
the ways in which they finance the health care
systems [18]. These countries are facing the
same challenges of how to provide the
population with affordable access to medicinal
products, with limited available public resources
[11]. Over the past ten years, average spending
per capita on medicinal products in EU countries
has risen by almost 50% in real terms. The
evidence for OECD countries suggests
considerable variation in medicinal products
spending, reflecting differences in volume,
structure of consumption and pharmaceutical
pricing policies [14].
In this article we aim to establish the
association between the regulated wholesale
prices of medicinal products and the public
expenditures for medicinal products. The public
expenditures on medicinal products in the
regression model are specified with emphasis
on the regulated wholesale prices of medicinal
products.
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1. Health Care System for Medicinal
Products in Non Hospital
Consumption in Slovenia
A linear increase in consumption of medicinal
products in Slovenia during the recent years
has been determined by a continuous increase
medicinal products treatment of an aging
population, an increased detection of chronic
diseases and complex therapeutic guidelines
[5]. In Slovenia there has been prescribing the
number of new, substantially more expensive
medicinal products for a similar or an entirely
new medical indication. Like in other developed
countries, the Slovenian population is more and
more informed about medical patients’ treatments.
Therefore, this has demanded more public
funds for consumption of medicinal products,
which have been prescribed by the medical
doctors on outpatient prescription (Rp). Those
reasons have been leading to a rising the public
expenditures for medicinal products in the
recent years in Slovenia. At the same time they
have caused a debate about the economic
efficiency of the public health system.
Therefore, the spending of the public funds and
the price regulation system for medicinal
products, they have increasingly been under
a scrutiny of government policy. Legislation,
regulatory and economic policy measures have
been used in Slovenia at aiming to reduce and
control public spending on medicinal products.
Each medicinal product that is present in
the Slovenian market must have valid
marketing authorization and should have set
a price. Medicinal products which are financed
from public funds should have regulated
wholesale prices in accordance with applicable
law. Medicinal products which compete for
entry on the list of medicinal products that are
wholly or partially financed by public funds
covered by the compulsory and supplementary
health insurance, they should have first formed
the wholesale price in accordance with the
applicable rules for the design and pricing of
medicinal products. The wholesale price is
determined by comparing the basket of reference
medicinal product prices or the reference price
or international or an external reference price.
These comparative countries are Germany,
France and Austria, which have replaced 
Italy in 2007. The system of the mutual
interchangeable medicinal products (MZZ) in
Slovenia is used to regulate prices of medicinal
products namely internal reference prices. This
system is applied only to some groups of
medicinal products organized in clusters having
the same active principle, strength and
formulation. The MZZ list with maximum
recognized value (MZZ z NPV) determinates
the maximum value that is covered by the
compulsory public health insurance. This is in
responsibility of the Standing Committee for
Medicinal Products. The additional decisions
for ranging the medicinal products in the lists
have been in the responsibility of the Public
Health Care Service of Slovenia. Medicinal
products can be classified in the positive list,
the intermediate list, by limiting the prescription
laid down by the Public Health Care Service of
Slovenia, or not classified that are on a negative
list [15]. Maximum recognized value (NPV) is
the price of the medicinal product, which is
covered by the Public Health Care Service of
Slovenia in accordance with the classification
of medicinal product on the lists: at 75% for
medicinal products at the positive list, at the
25% for medicinal products at the intermediate
list, and at 100% for specific examples. In 2009,
there have been made some changes. The
NPV is the price of the product value for each
medicinal product covered by the Public Health
Care Service of Slovenia in accordance with
the classification of the medicinal products on
the lists: at 100% for the positive list P100, at
75% for the positive list P75 and at 10% for the
intermediate list. If the price for medicinal
products is higher than the NPV, the patients
need to pay the difference between the actual
cost of medicinal product and the set NPV. The
final price of each medicinal product also increases
for the cost of margins, which are charged by
the dispensing pharmacy. The costs of pharmacy
services is not tied to the price of medicinal
products, but is fixed. It is defined in the
sectoral agreement for pharmaceutical activity.
The health care and health insurance
legislation in Slovenia provides compulsory and
voluntary health insurance, which affects the
manner of payments of costs for medicinal
products. The burden of compulsory health
insurance may be classified only for prescribed
medicines and foods for special purposes. The
compulsory health insurance covers at least
75% of the value of the positive list and
a maximum of 50% for the intermediate
medicinal product from the list. 
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The MZZ list entered into force in Slovenia
in November 2003. The initial list was compiled
by the competent authority for medicinal
products [15]. Since 2007, the Public Agency of
the Republic of Slovenia for Medicinal Products
and Medical Devices has updated this list. The
system operates on a comparison of the
scheduled medicinal products with the same
non-proprietary name or the same substance,
which corresponds to a number of brand names
of medicinal products with different prices. At
least one of the medicinal products with the same
non-proprietary name and comparable packaging
must be within the NPV. The introduction of the
MZZ has brought some positive economic
effects from a more rational prescribing of
medicinal products. These has occurred owing
from a larger share of a prescription of parallel
medicinal products with the lower price, and
owing from the lowering of prices of certain
medicinal products from manufacturers just
before and during the period following the
implementation of the MZZ by setting the NPV.
The effects were most noticeable in the first
years after the introduction of the system [15].
In Slovenia the ratio between the total costs
for medicinal products and the costs of
medicinal products, which were covered by the
Public Health Care Service of Slovenia, has
changed over the years. In 2000, 79.2% of all
costs for medicinal products were covered by
the Public Health Care Service of Slovenia,
while 63.8% in 2010 [15]. The total costs for
medicinal products and the share covered by
the Public Health Care Service of Slovenia
depend largely on the classification of
medicinal products on one of the lists and on
prices of medicinal products.
The study of developments of regulated
wholesale prices of medicinal products in
Slovenia in the period from 2003 to 2010
showed that the regulated wholesale prices of
medicinal products, which were publicly funded
and were prescribed on an outpatient Rp, have
been reduced over the analysed period. The
price regulation system of medicinal products in
Slovenia has become an important mechanism
for the control of public spending on pharma-
ceuticals. [9], [10]
2. Data Used in the Study
In this study we used data on the consumption
of medicinal products, which are published on
the website of the Public Health Care Service
of Slovenia and ranged them into the balanced
panel data, which were selected based on the
following criteria: medicinal products, data
available in all studied periods, and should
have regulated wholesale price, which financed
by public funds. We included the following
variables: public expenditures on medicinal
products prescribed in the outpatient Rp
covered by the compulsory health insurance,
the number of the Rp, the number of boxes of
medicinal products prescribed on the Rp,
wholesale prices of medicinal products and lists
on which the medicinal products were classified
(P100, P75, Q25 and Q10) . Data on the
number of the Rp, the number of boxes of
medicinal products prescribed on the Rp and
the value of medicinal products issued on the
Rp and covered by the compulsory health
insurance in Slovenia were obtained on the
website of the Public Health Care Service of
Slovenia. Data on wholesale prices of
medicinal products and classification of them
on the lists of medicinal products that are
wholly or partly funded from public resources
and information on the percentage of the value
of wholesale prices and the classification were
obtained on the basis of data from the Public
Health Care Service of Slovenia. The study
analyzed 758 medicinal products regulated
prices, financed from public funds in the years
2003–2010. These data are reported in the
nominal values. To obtain their real values over
the analysed years, the nominal values were
deflated by the consumer price index (CPI) with
the base year. The CPI deflators are obtained
from the Statistical Office of the Republic of
Slovenia. They are used to obtain the real price
values for medicinal products.
3. Methodology
We analyze the relationship between the
dependent variable and independent explanatory
variables by using the multivariate regression
analysis in order to estimate the model
parameters and the statistical significance of
the model.
The starting point of the empirical analysis
is the correlation analysis in order to examine
the degree of correlation between the pairs of
the analysed individual variables. Finally, the
regression analysis of the panel data by
employing the ordinary least square method is
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used to determine the relationship between the
public expenditures on medicinal products and
the wholesale price of medicinal products. The
regression analysis for the public expenditures
on outpatient medicinal products prescribed on
the Rp, which are covered by the Public Health
Care Service of Slovenia as the dependent
variable is specified by using the following
explanatory variables: the number of Rp, the
number of boxes of medicinal products prescribed
on the Rp, the wholesale price of medicinal
products and four dummy variables for the lists
on which the medicinal product is classified
(P100, P75, Q25 and Q10). Each dummy
variable takes the value 1 if the medicinal
product is classified at the appropriate list and
0 otherwise. Nominal values of the variables
are deflated by the CPI. The regression model
is estimated in natural logarithms, which means
that the regression coefficients at the same
time represent the coefficients of elasticity.
The null hypothesis assumes that public
expenditures for medicinal products, prescriptions
covered by the compulsory health insurance
are not associated with the wholesale price of
medicinal products, the number of boxes of
medicinal products prescribed per prescription
or the number of prescriptions of recipes and
the list at which the medicinal product is classified
(H0: θ = 0). The alternative hypothesis
assumes that public expenditures on medicinal
products, prescriptions covered by the compulsory
health insurance are associated with the
wholesale price of medicinal products, the
number of boxes of medicinal products
prescribed per prescription or the number of
prescriptions of recipes and the list at which the
medicinal product is classified (H1: θ ≠ 0).
4. Empirical Results
The correlation analysis showed that there is
a high positive correlation between the public
expenditures on medicinal products and the
number of Rp or the number of boxes
prescribed on the Rp, and there is a positive,
but relatively low correlation between the public
expenditures on medicinal products and the
wholesale price of medicinal product on one
hand and the classified list of medicinal
products on the other (Table 1).
The regression analysis confirmed that the
public expenditures for medicinal product are
positively associated with the number of the Rp
and the number of boxes prescribed on the Rp,
the wholesale price of medicinal product, and the
lists on which medicinal products are classified.
Tab. 1: 
Correlation coefficients and regressions for public expenditures for medicinal 
products in non hospital consumption in Slovenia
Dependent variable: public 
expenditures on medicinal Correlation coefficients Regression (1) Regression (2)
products
Explanatory variables:
Wholesale price 0.223*** 0.866*** 0.893***
Number of Rp 0.661*** 0.932***
Number of boxes on the Rp 0.670*** 0.971***
Positive list 100 0.031** 1.931*** 1.889***
Positive list 75 0.207** 1.510*** 1.667***
Intermediate list 25 -0.106*** 0.978*** 1.051***
N 6,064 6,064 6,064
Adjusted R2 0.896 0.937
F-test 10,446.3 18,096.9
Source: own
Note: *** p<0.001; ** p<0.05. Public expenditures on medicinal products, the wholesale price, the number of the Rp
and the number of boxes on the Rp are expressed in natural logarithms.
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5. Discussion
The correlation and regression analysis
confirmed a positive association between the
wholesale price of medicinal product and the
public expenditures for medicinal products.
There was also a positive association between
the public expenditures for medicinal products
and the number of the Rp or the number of
boxes required on the Rp. The explanatory
variables included in the regression model
explained 94% of the variability of the public
expenditures for medicinal product. The set
dummy variables for the list classification
(P100, P75 and Q25) were positively associated
with the public expenditures for medicinal
products. Elasticity coefficients indicate that an
increase the number of the Rp for 1% leads to
an increase in the public expenditures for
medicinal products by 0.932%. The increase in
the number of boxes of medicinal products
prescribed on the Rp by 1% leads to an
increase in the public expenditures for medicinal
products by 0.971%. The increase in the
wholesale price of medicinal products prescribed
on the Rp by 1% leads to an increase in the
public expenditures for medicinal products by
0.866% or 0.893%. The previous analysis ([9]
and [10]) confirmed that the wholesale prices of
medicinal products have declined during the
price regulation system. The empirical results
confirmed that the public expenditures for
medicinal products issued on the Rp, which are
covered by the compulsory health insurance,
are related to the number of the Rp or the
number of boxes prescribed on the Rp and the
wholesale price of medicinal products and the
lists to which the medicinal products are
classified. The public expenditures for
medicinal products are affected by the number
of prescribed medicinal products, which are
issued by the Rp and the number of boxes of
medicinal product, which are prescribed on the
Rp, and the developments of the regulated
wholesale prices for medicinal products.
The empirical analysis confirmed the
alternative H1 hypothesis, which says that
there is a positive association of the public
expenditures for medicinal products with the
number of boxes of medicinal product, which
prescribed on the Rp, the number of the Rp
prescriptions, the wholesale price of medicinal
products and the lists to which the medicinal
product is classified.
The regulated wholesale price affects the
public expenditures for medicinal products, but
on the public expenditures for medicinal
products has a significant positive impact also
the number of the Rp or the number of boxes of
medicinal products, which are prescribed on
the Rp. Effective, safe and quality treatment of
patients with medicinal products is not
proportional to the number of medicinal
products that each patient receives. The aim of
pharmacological treatment is the best possible
quality of life of patients. Safe and effective
quality treatment and consequently cost-
effective medical treatment depends largely on
a correct assessment of a medical doctor
regarding medical conditions for the individual
patient that should be treated with medicinal
products. Crucial is the responsible prescribing
of medicinal products on the RP. The
consumption of medicinal products in Slovenia
measured in the defined daily doses in the last
ten years increased, while the number of
persons, who received this medicine, has not
significantly increased. This suggests that the
same people received more medicinal products
and the consumption of medicinal products per
beneficiary has increased over time. There is
an increased risk of adverse interaction and
negative reaction on medicinal products use,
and more difficult is to manage costs for
medicinal products in a sustainable way vis-à-
vis budgetary limitations. The polipharmacy –
the co-administration of five or more medicinal
products simultaneously – is in the exceptional
growth, which to some extent also leads to
increasing health damages and additional
economic costs. The responsible prescribing of
medicinal products, which requires consideration
of medical and economic aspects of prescription
of medicinal products, is of a substantial
relevance. The prescribing of medicinal
products should be derived from the medicinal
findings of which medicinal products are really
necessary to treat patients and at the same
time to reduce irrational prescribing. For more
responsible and proper use of medicinal
products it is necessary to inform and educate
patients in order to consider rational use and to
prevent irrational behaviour which requires
prescription of medicinal products without
adequate medical treatment.
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Conclusions
The regression analysis has confirmed that the
public expenditures for medicinal products
were a positively associated with the regulated
wholesale prices of medicinal products. This
implies the decrease in the wholesale prices of
medicinal products has caused the decrease in
the public spending for medicinal products. The
results of the regression analysis confirmed the
relationship between the lists on which the
medicinal product is classified and the public
expenditures for medicinal products. The public
expenditures for medicinal products were also
significantly determined by the number of
prescribed Rp and the number of boxes of
medicinal products on the Rp prescription. In
the regression model included variables
explained a high percentage of the public
expenditures for medicinal products. To
a lesser extent the regression results are
affected by some other factors, which were not
specified in regression model such as value-
added tax and pharmacy services. The
regulation of the wholesale prices for medicinal
products and encouraging more conservative
prescribing could play an important role in
management of public spending for medicinal
products [16]. The consumption of medicinal
products in Slovenia has increased over time.
New medicinal products and new areas of
medical treatments, higher prescribed doses of
medicinal products, aging of the population and
the related polipharmacy, have rapidly
increased costs for use of medicinal products.
They go beyond the sustainable financial ability
of the Public Health Care Service of Slovenia.
This situation is similar to the public health
systems in most of developed countries.
Therefore, to reduce costs and public health
expenditures is a challenging issue for both
health and overall economic and budgetary
policy.
They [4] noted that in the early 1990s, most
of governments in Europe decided to
implement a mixture of different health policies
and policies towards consumption of medicinal
products, which are financed from the public
funds. These policies focus on the price regulation
for medicinal products or on the prescribed
amount of medication or a combination of both.
The practical experiences confirmed the crucial
importance of mix of fair pricing policy and
regulation quantities for medicinal products. As
the regression analysis confirmed the public
financing expenses were significantly positively
associated with the number of Rp and the
number of boxes prescribed on the Rp. This
reflects the importance of the pricing policy and
regulation quantities for medicinal products,
which were intended for consumption financed
by the public expenditures.
Rational prescribing of medicinal products
and their rational use in accordance with the
medical instructions are the factors that could
affect the costs and public expenditures for
medicinal products without reductions of the
rights of insured for medical products. Rational
prescribing of medicinal products could not be
considered as a measure for limiting the access
to medicinal products, but rather the appropriate
way of utilization of limited available public
resources for medicinal products. The
monitoring of the expenditures for medicinal
products in Slovenia has included regulated
pricing, scheduling of medicinal products on the
lists (the system of the MZZ with NPV and
medicinal products with limited prescription),
education and information for medical doctors,
pharmacists and users on the appropriate and
rational management in the use of medicinal
products. The aim in Slovenia has been to
reduce the public expenditures for medicinal
products. This has been included in the regime
of medical treatments, which allows the
inclusion of new and more effective medicinal
products in the health system.
The article does not address the issues of
consumption of medicinal products, which were
used in hospitals ([8] and [13]). The reason for
this lies in a fact that the observed period was
not accompanied by data on the use of
medicinal products in the hospitals. The prices
of medicinal products in the hospitals were
determined by the similar procedure as the
prices of medicinal products with the Rp
prescription. The consumption of medicinal
products in hospitals is an issue future
research.
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Abstract
DETERMINANTS OF PUBLIC EXPENDITURES FOR MEDICINAL PRODUCTS
IN NON HOSPITAL CONSUMPTION IN SLOVENIA
Romana KajdiÏ, ·tefan Bojnec
The Slovenian government aims to regulate prices for medicinal products to manage and reduce
public expenditures for medicinal products. This paper aims to investigate the association between
the regulated wholesale prices of medicinal products and the public expenditures for medicinal
products, and to estimate regression model for public expenditures for medicinal products in the
non hospital consumption. In the empirical research are included 758 regulated prices for medicinal
products prescribed by the outpatients’ department on a prescription (Rp) during the years
2003–2010, which are financed from public expenditures. The correlation and regression analyses
are used in order to establish the association between the regulated wholesale prices for medicinal
products and the public expenditures for medicinal products. The correlation analysis confirmed
a strong positive correlation of the public expenditures for medicinal products with the number of
Rp or the number of boxes on the Rp prescription, a weak correlation with the wholesale prices for
medicinal products and with the classification lists of medicinal products. The multiple regression
analysis confirmed a positive significant impact of the wholesale price of medicinal products and
the number of Rp or the number of boxes on the Rp prescription, on the public expenditures for
medicinal products. The research has confirmed the association of the public expenditures for
medicinal products with the regulated wholesale prices for medicinal products. It has underlined the
importance of the rational prescription and use of medicinal products. The explanatory variables
included in the regression model for the public expenditures for medicinal products explained up to
94% of variability in the public expenditures for medicinal products.
Key Words: Price regulation, medicinal products, prescription management, public
expenditures, Slovenia.
JEL Classification: H51.
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